Shikha Wadhwani , Sarah A. Mansfield , Abigail R. Smith , Bruce M. Robinson , Eman Abdelghani , Amira Al-Uzri , Isa F. Ashoor , Sharon M. Bartosh , Aftab S. Chishti , Salim S. Hayek , Michelle A. Hladunewich , Bryce A. Kerlin , Siddharth S. Madapoosi , Laura H. Mariani , Amy K. Mottl , Michelle N. Rheault , Michelle M. O’Shaughnessy , Christopher John Sperati , Tarak Srivastava , David T. Selewski , Myda Khalid
{"title":"Cardiovascular and Thromboembolic Events in Children and Adults With Glomerular Disease: Findings From the Cure GlomeruloNephropathy (CureGN) Network","authors":"Shikha Wadhwani , Sarah A. Mansfield , Abigail R. Smith , Bruce M. Robinson , Eman Abdelghani , Amira Al-Uzri , Isa F. Ashoor , Sharon M. Bartosh , Aftab S. Chishti , Salim S. Hayek , Michelle A. Hladunewich , Bryce A. Kerlin , Siddharth S. Madapoosi , Laura H. Mariani , Amy K. Mottl , Michelle N. Rheault , Michelle M. O’Shaughnessy , Christopher John Sperati , Tarak Srivastava , David T. Selewski , Myda Khalid","doi":"10.1016/j.xkme.2024.100877","DOIUrl":null,"url":null,"abstract":"<div><h3>Rationale & Objective</h3><div>Cardiovascular (CV) and thromboembolic (TE) events are known complications of glomerular disease (GD), but their incidence and risk factors are poorly characterized. This analysis describes CV and TE outcomes in the Cure GlomeruloNephropathy (CureGN) Network.</div></div><div><h3>Study Design</h3><div>Prospective cohort study.</div></div><div><h3>Setting & Participants</h3><div>CureGN is a prospective cohort study of children and adults with biopsy-proven minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN), or IgA nephropathy (IgAN)/vasculitis (IgAV). Data from 2,545 children and adults (23% MCD, 23% MN, 25% FSGS, 29% IgAN/IgAV) was analyzed.</div></div><div><h3>Exposure</h3><div>Estimated glomerular filtration rate (eGFR), proteinuria, serum albumin, tobacco use, body mass index, hypertension, renin-angiotensin-aldosterone system.</div></div><div><h3>Outcomes</h3><div>CV and TE events.</div></div><div><h3>Analytic Approach</h3><div>Kaplan–Meier curves were used to estimate cumulative incidence, and multivariable Cox proportional hazards models were fitted to estimate associations of histologic diagnosis, age, biological sex, and race. Laboratory and other clinical data were evaluated separately in models adjusted for base model covariates.</div></div><div><h3>Results</h3><div>Median follow-up time was 4.6 years (IQR 2.7-6.1). The cumulative incidence of first CV and TE event postbiopsy was 3% and 2% in children and 10% and 5% in adults, respectively. No association between GD subtype and risk of CV or TE event was detected. Older age and Black race were associated with higher risk of first CV and TE event {hazard ratio (HR) (95% confidence interval {CI}) per 5 years, CV<!--> <!-->=<!--> <!-->1.17 (1.12-1.23); TE<!--> <!-->=<!--> <!-->1.11 (1.05-1.18); for Black race, CV<!--> <!-->=<!--> <!-->1.62 (1.03-2.56), TE<!--> <!-->=<!--> <!-->2.25 (1.27-4.01)}. Lower eGFR, higher urinary protein-creatinine ratio (UPCR), and lower serum albumin levels at enrollment were associated with higher risk of first CV and TE event (eGFR per 10<!--> <!-->mL/min/1.73<!--> <!-->m<sup>2</sup>, CV<!--> <!-->=<!--> <!-->0.87 [0.81-0.93], TE<!--> <!-->=<!--> <!-->0.80 [0.73-0.88]; UPCR per mg/mg, CV<!--> <!-->=<!--> <!-->1.04 [1.02-1.07], TE<!--> <!-->=<!--> <!-->1.03 [1.00-1.07]; serum albumin per g/dL, CV<!--> <!-->=<!--> <!-->0.75 [0.59-0.95], TE<!--> <!-->=<!--> <!-->0.71 [0.53-0.96]).</div></div><div><h3>Limitations</h3><div>Age of cohort, duration of follow-up.</div></div><div><h3>Conclusions</h3><div>In the CureGN cohort, elevated risk of incident CV and TE events is associated with severity of kidney disease rather than GD subtype.</div></div><div><h3>Plain-Language Summary</h3><div>Individuals with glomerular disease are at risk for cardiovascular and thromboembolic events. The aim of our study was to determine the frequency and risk factors for such events in adults and children with minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, and IgA nephropathy/vasculitis enrolled in the CureGN study. Our ultimate goal is to equip physicians with tools to identify high-risk individuals and help develop mitigative therapies. We found that poor kidney function, low serum albumin level, and high levels of urine protein at the time participants entered the study, along with older age and self-reported Black race were associated with a higher risk of both cardiovascular and thromboembolic events. In addition, these risk factors are more important than the specific type of glomerular disease.</div></div>","PeriodicalId":17885,"journal":{"name":"Kidney Medicine","volume":"7 6","pages":"Article 100877"},"PeriodicalIF":3.4000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kidney Medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590059524000888","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/20 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Rationale & Objective
Cardiovascular (CV) and thromboembolic (TE) events are known complications of glomerular disease (GD), but their incidence and risk factors are poorly characterized. This analysis describes CV and TE outcomes in the Cure GlomeruloNephropathy (CureGN) Network.
Study Design
Prospective cohort study.
Setting & Participants
CureGN is a prospective cohort study of children and adults with biopsy-proven minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN), or IgA nephropathy (IgAN)/vasculitis (IgAV). Data from 2,545 children and adults (23% MCD, 23% MN, 25% FSGS, 29% IgAN/IgAV) was analyzed.
Exposure
Estimated glomerular filtration rate (eGFR), proteinuria, serum albumin, tobacco use, body mass index, hypertension, renin-angiotensin-aldosterone system.
Outcomes
CV and TE events.
Analytic Approach
Kaplan–Meier curves were used to estimate cumulative incidence, and multivariable Cox proportional hazards models were fitted to estimate associations of histologic diagnosis, age, biological sex, and race. Laboratory and other clinical data were evaluated separately in models adjusted for base model covariates.
Results
Median follow-up time was 4.6 years (IQR 2.7-6.1). The cumulative incidence of first CV and TE event postbiopsy was 3% and 2% in children and 10% and 5% in adults, respectively. No association between GD subtype and risk of CV or TE event was detected. Older age and Black race were associated with higher risk of first CV and TE event {hazard ratio (HR) (95% confidence interval {CI}) per 5 years, CV = 1.17 (1.12-1.23); TE = 1.11 (1.05-1.18); for Black race, CV = 1.62 (1.03-2.56), TE = 2.25 (1.27-4.01)}. Lower eGFR, higher urinary protein-creatinine ratio (UPCR), and lower serum albumin levels at enrollment were associated with higher risk of first CV and TE event (eGFR per 10 mL/min/1.73 m2, CV = 0.87 [0.81-0.93], TE = 0.80 [0.73-0.88]; UPCR per mg/mg, CV = 1.04 [1.02-1.07], TE = 1.03 [1.00-1.07]; serum albumin per g/dL, CV = 0.75 [0.59-0.95], TE = 0.71 [0.53-0.96]).
Limitations
Age of cohort, duration of follow-up.
Conclusions
In the CureGN cohort, elevated risk of incident CV and TE events is associated with severity of kidney disease rather than GD subtype.
Plain-Language Summary
Individuals with glomerular disease are at risk for cardiovascular and thromboembolic events. The aim of our study was to determine the frequency and risk factors for such events in adults and children with minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, and IgA nephropathy/vasculitis enrolled in the CureGN study. Our ultimate goal is to equip physicians with tools to identify high-risk individuals and help develop mitigative therapies. We found that poor kidney function, low serum albumin level, and high levels of urine protein at the time participants entered the study, along with older age and self-reported Black race were associated with a higher risk of both cardiovascular and thromboembolic events. In addition, these risk factors are more important than the specific type of glomerular disease.